Technology evaluation: huN901-DM1, ImmunoGen.

Suzanne V Smith

PubMed · 16121706

Technology evaluation: huN901-DM1, ImmunoGen.

Abstract

ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer.

Explore related subjects

Ado-Trastuzumab Emtansine Animals Antibodies, Monoclonal Antibodies, Monoclonal, Humanized CD56 Antigen Carcinoma, Small Cell Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Humans Lung Neoplasms Maytansine Prodrugs Trastuzumab Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Suzanne V Smith. 2005. Technology evaluation: huN901-DM1, ImmunoGen.. https://pubmed.ncbi.nlm.nih.gov/16121706/

Cite the original work for its findings. Save a collection to share your selection of sources.